Module home
Module introduction
Pre-module test
Module information
About the author
Section 1: What is
treatment-resistant depression?
(1.1) Section 1: What is treatment-resistant depression?
(1.2) Clinical pointers
(1.3) Stages of treatment resistance
(1.4) Further stages of antidepressant treatment resistance
(1.5) Section 1: Recap
(1.6) Section 1:
Summary
Section 2: Switching
antidepressants
(2.1) Section 2: Switching antidepressants
(2.2) How to switch antidepressants
(2.3) Are some antidepressants better than others?
(2.4) A comparison of venlafaxine with other antidepressants
(2.5) Guidance on venlafaxine
(2.6) Indications for MAOI treatment in TRD
(2.7) Section 2: Recap
(2.8) Section 2:
Summary
Section 3:
Augmentation
(3.1) Section 3: Augmentation
(3.2) Augmentation
(3.3) Antidepressant combinations
(3.4) Lithium
(3.5) Antipsychotic drugs
(3.6) Response rates to antipsychotic and antidepressant
treatments
(3.7) Atypical antipsychotic drugs
(3.8) Atypical antipsychotic augmentation: olanzapine
(3.9) Atypical antipsychotic augmentation: risperidone
(3.10) Atypical antipsychotic augmentation: quetiapine
(3.11) Atypical antipsychotic augmentation: aripiprazole
(3.12) Section 3: Recap
(3.13) Section 3:
Summary
Section 4: Other therapies and
depression in bipolar illness
(4.1) Section 4: Other therapies and depression in bipolar
illness
(4.2) Electroconvulsive therapy
(4.3) Cognitive-behavioural therapy
(4.4) Problems with treating depression in bipolar illness
(4.5) Treatment of depression in the bipolar spectrum
(4.6) Section 4: Recap
(4.7) Section 4:
Summary
Module summary
Module test
Take-home notes
References
Send feedback
Annual revisions
Annual revisions
|